BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory motivation to maintain current attitudes and beliefs, but weak enough that the receiver will refute the counterargument (Compton, 2013; McGuire, 1964). Inoculation has been proven successful through trials and research. This article highlights vital aspects of inoculation theory, however, it is not exhaustive–there is a large volume of quality research on the theory not mentioned. Finally, while numerous studies have tested and verified the efficacy of the inoculation process, there continues to be a need for refinement and elaboration. Inoculation theory is used today as part of the suite of tools used by those engaged in shaping or manipulating public